We selected Chidamide, a specific inhibitor of Class I and II HDACs, including HDAC1, HDAC2, HDAC3, and HDAC10, which showed a significant association with DLBCL in our bioinformatic analyses. Here, HDAC2 is linked to diffuse large B-cell lymphoma.